← Back to headlines
Citi Initiates Neutral Rating for BridgeBio
Citi has begun its coverage of BridgeBio with a neutral rating, expressing caution about the company's cardiomyopathy story as a guaranteed success.
19 May, 16:15 — 19 May, 16:15
Sources
Showing 1 of 1 sources
